Calls for papers
-
BiomX announced that it has initiated a Phase 2b study of its BX004 inhaled phage cocktail cystic fibrosis patients with chronic P. aeruginosa lung infections. BiomX had said in November 2023 that it planned to advance… Read more . . .
-
Oragenics, which recently announced that it had raised approximately $16.5 million for Phase 2 development of its OPN-002 neurosteroid nasal powder for the treatment of mild traumatic brain injury, says that Sterling Pharma Services will… Read more . . .
-
Aptar Pharma announced that it has acquired OINDP specialist CDMO Mod3 Pharma (formerly Enteris Biopharma). According to Mod3’s web site, Enteris was created in 2013 with assets and personnel from Unigene, which manufactured Fortical calcitonin… Read more . . .
-
Hong Kong-based Guangdong Hengrui Pharmaceuticals’s parent company Jiangsu Hengrui Pharmaceuticals announced that Guangdong Hengrui has received approval from the Chinese National Medical Products Administration (NMPA) for a clinical trial of its HRS-9821 DPI, which the… Read more . . .
-
Merck has announced that it will acquire Ohtuvarye inhaled ensifentrine maker Verona Pharma for a total of approximately $10 billion. Ohtuvarye, which is delivered via jet nebulizer, was approved by the FDA in June 2024… Read more . . .
-
Evoke Pharma announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a continuation of US Patent No. 11,517,545 (“Treatment of Moderate and Severe Gastroparesis”), which was issued… Read more . . .
-
Oragenics announced that it has raised approximately $16.5 million in a Series H funding round, with proceeds going toward repayment of a $3 million bridge loan and continued development of the company’s OPN-002 neurosteroid nasal… Read more . . .
-
German startup Ebenbuild has received a €2.3 million grant plus a commitment for up to an additional €10 million in future investments from the European Innovation Council (EIC) Accelerator program, the company said. The funding… Read more . . .
-
Beckley Psytech and atai Life Sciences have announced that a Phase 2b trial of Beckley’s BPL-003 intranasal mebufotenin (5-MeO-DMT) in patients with treatment-resistant depression met its primary endpoint, demonstrating a significant reduction in symptoms of depression… Read more . . .
-
Intranasal drug developer Vistagen has announced the appointment of Elissa Cote as Chief Corporate Development Officer. According to her LinkedIn page, Cote served as a strategic advisor to Narcan nasal spray developer Emergent Biosolutions from January 2023 to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA